Faculty of Chemistry & Chemical Biology, TU Dortmund University , Otto-Hahn-Str. 6, 44227 Dortmund, Germany.
ACS Chem Biol. 2014 Jan 17;9(1):57-71. doi: 10.1021/cb4008277. Epub 2014 Jan 6.
The field of regenerative medicine has boomed in recent years thanks to milestone discoveries in stem cell biology and tissue engineering, which has been driving paradigm shifts in the pharmacotherapy of degenerative and ischemic diseases. Small molecule-mediated replenishment of lost and/or dysfunctional tissue in vivo, however, is still in its infancy due to a limited understanding of mechanisms that control such endogenous processes of tissue homeostasis or regeneration. Here, we discuss current progress using small molecules targeting in vivo aspects of regeneration, including adult stem cells, stem cell niches, and mechanisms of homing, mobilization, and engraftment as well as somatic cell proliferation. Many of these compounds derived from both knowledge-based design and screening campaigns, illustrating the feasibility of translating in vitro discovery to in vivo regeneration. These early examples of drug-mediated in vivo regeneration provide a glimpse of the future directions of in vivo regenerative medicine approaches.
近年来，得益于干细胞生物学和组织工程学的里程碑式发现，再生医学领域蓬勃发展，这推动了退行性和缺血性疾病药物治疗的范式转变。然而，由于对控制组织内稳态或再生等内源性过程的机制的理解有限，小分子介导的体内失活和/或功能障碍组织的补充仍处于起步阶段。在这里，我们讨论了使用小分子靶向体内再生方面的最新进展，包括成体干细胞、干细胞龛和归巢、动员和植入以及体细胞增殖的机制。这些化合物中有许多来自基于知识的设计和筛选活动，这说明了将体外发现转化为体内再生的可行性。这些药物介导的体内再生的早期例子提供了一个展望体内再生医学方法未来方向的机会。
